Filing Analysis
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the second quarter ended June 30, 2026.
📋 Key Facts
- Report date: August 5, 2026
- Reporting period: Three months ended June 30, 2026
- The filing is an announcement of quarterly earnings (Item 2.02)
- Press release issued as Exhibit 99.1
RxSight, Inc. announced a leadership transition where Aziz Mottiwala will become President and CEO effective July 20, 2026, replacing Dr. Ron Kurtz, who will transition to Chief Medical Officer. The filing details significant new compensation packages for both the incoming CEO and the transitioning CMO.
🚩 Red Flags
- Significant equity grant ($14M) for a new CEO in a micro-cap context may indicate high dilution or aggressive compensation structure.
- The transition of a long-tenured CEO (since 2016) to a CMO role, while described as non-dispute related, often warrants monitoring for underlying strategic shifts.
📋 Key Facts
- Aziz Mottiwala appointed as President and CEO, effective July 20, 2026.
- Dr. Ron Kurtz transitions from CEO to Chief Medical Officer; he also resigned from the Board of Directors.
- Mottiwala's compensation includes a $750,000 base salary and up to $14,000,000 in new equity awards (options and RSUs).
- Dr. Kurtz's transition agreement includes a $740,000 base salary and potential retention bonuses of $370,000 on four specific dates through 2028.
- Mottiwala's severance package includes up to 18 months of salary/bonus in the event of a change in control.
RxSight, Inc. issued an 8-K to announce the release of preliminary unaudited financial and operational results for the second quarter of 2026.
📋 Key Facts
- Report date: July 06, 2026
- The filing pertains to Item 2.02 (Results of Operations and Financial Condition)
- Information is preliminary and unaudited
- Company issued a press release as Exhibit 99.1 containing the results
RxSight, Inc. entered into a significant collaboration agreement with Alcon Pharmaceuticals to develop and commercialize light-adjustable versions of Alcon's SVIOL intraocular lenses using RxSight's Light Adjustable Technology™. The deal includes substantial upfront payments and milestone opportunities.
🚩 Red Flags
- Restrictive covenants: RxSight is restricted from developing certain competing hybrid material SVIOLs during the development phase.
- Penalty clauses: If RxSight develops competing products after the phase, they face 60%+ royalty reductions, suspension of Alcon's minimum royalties, and potential reimbursement of upfront/milestone payments.
📋 Key Facts
- Effective Date: June 30, 2026.
- Upfront cash payment from Alcon to RxSight: $60 million.
- Feasibility Milestone Payment option for Alcon: $70 million.
- FDA submission milestone payment: $30 million upon first submission of the first Collaboration Product.
- Approval Milestone Payment option for Alcon: $40 million upon regulatory approval of the first product.
- Royalty structure: 30% on net sales of all Collaboration Products.
- RxSight will exclusively supply the Collaboration Products to Alcon and is responsible for installing/servicing Light Delivery Devices (LDD) in the U.S.
RxSight, Inc. has finalized a transition agreement for its Chief Financial Officer, Shelley Thunen, which includes a consulting arrangement to provide transition services following her separation.
🚩 Red Flags
- CFO departure can sometimes signal internal friction or disagreements over financial reporting, though no restatement was mentioned here.
📋 Key Facts
- Shelley Thunen is transitioning from her role as CFO and principal financial/accounting officer.
- The Company and Ms. Thunen entered into a Transition Agreement and a Consulting Agreement effective upon her separation date.
- The leadership transition is not expected to impact the Company's full-year 2025 outlook or strategic priorities.
RxSight, Inc. announced that CFO Shelley Thunen will transition from her role effective either upon the appointment of a successor or January 31, 2026. The company has arranged for Ms. Thunen to serve as a consultant through December 31, 2026, to ensure a smooth transition.
🚩 Red Flags
- Unexpected departure of a key executive (CFO).
📋 Key Facts
- Shelley Thunen notified the company of her intention to transition from CFO and principal financial/accounting officer on Dec 16, 2025.
- Transition effective date: Sooner of successor appointment or January 31, 2026.
- Ms. Thunen will enter into a consulting agreement through December 31, 2026.
- Consulting compensation includes non-refundable retainers of $15,000 for Jan, Feb, and March 2026 (if terminated without cause) and an hourly rate of $500.
- Outstanding stock options will continue to vest under original terms during the consulting period.
RxSight, Inc. announced two executive leadership changes effective December 18, 2025. Eric Weinberg is transitioning from Chief Commercial Officer to Chief Business Development Officer, and Scott Gaines has been appointed as the new Chief Customer Officer.
🚩 Red Flags
- Internal reshuffling of key commercial leadership (CCO to CBDO) can sometimes indicate a shift in strategic focus or internal reorganization.
📋 Key Facts
- Eric Weinberg transitioned from Chief Commercial Officer (CCO) to Chief Business Development Officer on December 18, 2025.
- Scott Gaines was appointed as Chief Customer Officer, overseeing the U.S. commercial organization, effective December 18, 2025.
- The changes were approved by the Board of Directors.
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three and nine months ended September 30, 2025.
📋 Key Facts
- Report date: November 05, 2025
- Reporting period: Three and nine months ended September 30, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
This 8-K/A amendment reports the appointment of Raymond W. Cohen to the Compensation Committee and Audit Committee of the Board, effective August 14, 2025.
📋 Key Facts
- Amendment to an original 8-K filed on August 4, 2025.
- Raymond W. Cohen was previously appointed to the Board of Directors effective July 31, 2025.
- As of August 14, 2025, Mr. Cohen joined the Compensation Committee.
- As of August 14, 2025, Mr. Cohen joined the Audit Committee.
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three and six months ended June 30, 2025.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Three and six months ended June 30, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
RxSight, Inc. expanded its Board of Directors from nine to ten members with the appointment of Raymond W. Cohen as a Class I director, effective July 31, 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Board size increased from nine to ten directors.
- Raymond W. Cohen appointed as a non-employee director (Class I) effective July 31, 2025.
- Mr. Cohen's term expires at the 2028 annual meeting of stockholders.
- Initial compensation includes an RSU award with a grant date fair value of $277,500, vesting ratably over three years.
- Standard indemnification agreement entered into with Mr. Cohen.
RxSight, Inc. issued a Form 8-K to announce the release of preliminary unaudited second quarter financial and operational results for the period ending June 2025.
📋 Key Facts
- The filing was made on July 8, 2025.
- Company announced preliminary unaudited Q2 financial and operational results via press release (Exhibit 99.1).
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18 of the Exchange Act.
RxSight, Inc. held its 2025 Annual Meeting of Stockholders on June 3, 2025. The meeting resulted in the re-election of three Class I directors and the advisory approval of executive compensation and the appointment of Ernst & Young LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 3, 2025.
- Quorum reached with 32,181,609 shares represented (approx. 79.2% of outstanding common stock).
- Re-election of Class I Directors: Ron Kurtz, M.D., J. Andy Corley, and Juliet Tammenoms Bakker.
- Advisory vote on executive compensation was approved by stockholders.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2025.
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three months ended March 31, 2025.
📋 Key Facts
- Report date: May 7, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
RxSight, Inc. issued an 8-K to announce the release of preliminary unaudited financial and operational results for the first quarter of 2025.
📋 Key Facts
- The filing was made on April 2, 2025, regarding events occurring on the same date.
- The company is providing preliminary unaudited Q1 2025 financial and operational results via a press release (Exhibit 99.1).
- Information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three and twelve months ended December 31, 2024.
📋 Key Facts
- Report date: February 25, 2025
- Reporting period: Three and twelve months ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results
- Filed under Item 2.02 (Results of Operations and Financial Condition)
RxSight, Inc. issued a press release announcing its preliminary unaudited financial and operational results for the fourth quarter and full year of 2024.
📋 Key Facts
- Report date: January 12, 2025
- Content: Preliminary unaudited Q4 and Full-Year 2024 financial/operational results
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three and nine months ended September 30, 2024.
📋 Key Facts
- Report date: November 7, 2024
- Reporting period: Three and nine months ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial performance.
- Filed under Item 2.02 (Results of Operations and Financial Condition).
RxSight, Inc. filed an 8-K to announce its quarterly results of operations and financial condition for the periods ended June 30, 2024.
📋 Key Facts
- Reporting period: Three and six months ended June 30, 2024.
- Filing date: August 5, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial performance.
RxSight, Inc. held its 2024 Annual Meeting of Stockholders on June 6, 2024. The meeting resulted in the re-election of three Class III directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 6, 2024.
- Quorum represented approximately 80.8% of outstanding shares (30,022,322 shares out of 37,173,544 total).
- Julie B. Andrews, Robert J. Palmisano, and Tamara R. Fountain, M.D. were re-elected to the Board as Class III directors.
- Stockholders approved executive compensation on an advisory basis.
- Stockholders voted for 'ONE YEAR' frequency for future advisory votes on executive compensation.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2024.
RxSight, Inc. entered into an underwriting agreement to conduct a public offering of 1,785,714 shares of common stock at $56.00 per share. The offering is expected to generate approximately $93.2 million in net proceeds and is anticipated to close on May 13, 2024.
🚩 Red Flags
- Equity dilution: The issuance of over 1.7 million new shares will dilute existing shareholders.
📋 Key Facts
- Offering size: 1,785,714 shares of common stock.
- Offering price: $56.00 per share.
- Underwriters include BofA Securities, Inc. as representative.
- Expected net proceeds: Approximately $93.2 million after expenses and discounts.
- Includes an over-allotment option for underwriters to purchase up to 267,857 additional shares.
- Lock-up period: Executive officers and directors are subject to a 60-day lock-up agreement.
RxSight, Inc. filed an 8-K to announce its quarterly results of operations and financial condition for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Three months ended March 31, 2024
- The filing serves to provide the quarterly earnings press release (Exhibit 99.1)
RxSight, Inc. entered into one new lease and two amendments to existing leases for its facilities in Aliso Viejo, California, to secure long-term access and expand manufacturing capacity.
🚩 Red Flags
- Increased long-term fixed operating obligations (lease liabilities).
📋 Key Facts
- Entered into a new lease (125 Columbia Lease) with BML Management, LLC for ~26,825 sq. ft., starting June 1, 2024, ending Jan 31, 2031.
- Base rent for the new lease is $41,579 per month.
- Amended '5 Columbia' lease to extend term by 70 months (April 1, 2025 – Jan 31, 2031) with base rent of $30,701/month.
- Amended '100 Columbia' lease to extend term by 76 months (Oct 1, 2024 – Jan 31, 2031) with base rent of $64,843/month.
- Total future minimum lease payments under these agreements amount to approximately $10.8 million.
- Lease terms include multiple 60-month extension options for each facility.
RxSight, Inc. filed an 8-K to announce its results of operations and financial condition for the three and twelve months ended December 31, 2023.
📋 Key Facts
- Report date: February 28, 2024
- Reporting period: Three and twelve months ended December 31, 2023
- The filing includes a press release as Exhibit 99.1 regarding financial results.
RxSight, Inc. issued an 8-K to announce the release of preliminary unaudited financial and operational results for the fourth quarter and full year of 2023.
📋 Key Facts
- The filing relates to preliminary unaudited Q4 and Full Year 2023 financial/operational results.
- Results were announced via press release on January 7, 2024.
- Information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.